Posts Tagged Cloud
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship on February 26, 2020
PeterDrucker has famously said, “The best way to predict the future is to create it.” And that is the central core of the theme at TiEcon 2020.
If you are an entrepreneur then TiEcon 2020 is the place where you want to CONVERGE. There’s plenty here for entrepreneurs. You might find just find the right idea, timely advice, meet a mentor, pair up with a partner, or perhaps connect with an interested investor. Very likely an entrepreneur is likely to find something here that will be a catalyst for them to begin to CREATE the environment to bring that innovation to fruition. TiEcons have always offered an environment to ELEVATE innovation from earliest idea stage to its fullest potential.
TiEcon 2020 tracks are announced and they are extremely relevant to current environment and very exciting. In the coming weeks, you will hear a great deal about the tracks, speakers, and keynotes. There are tracks and events that may offer something for all attendees like entrepreneurship and startup bootcamp. And then there are tracks that we all hear about and are on the cutting edge of new developments like cloud, security, IOT and ML. There are also tracks and events that feature the human side of an organization and soft mentoring side of this conference like diversity and inclusion and global and mentor connect, and young entrepreneurs.
With convergence of well over 4500 attendees, 220 speakers, 13+ tracks, 1300 industry leaders, from 22+ countries, there is something here for every entrepreneur to sow the seeds for creation of that innovative idea into something magnificent or elevate it to something amazing. If you are intrigued, remember it all starts with convergence at TiEcon 2020. Registration is open at early bird price at www.tiecon.org .
Aroon Krishna and David Judelson, co-founders at VirtuMed talked about the challenging environment for current medical device manufacturers and VirtuMed’s Synapse Mobile cloud based, on-demand, customer engagement platform solution to address the challenges, at a recent www.bio2devicegroup.org event.
Enumerating examples of challenges impacting medical device marketplace, Judelson, said Boston Scientific neuro modulation business has declined due to reimbursement challenges, Medtronic agreed to settle and stop the sales of pain med pump due to link with patient deaths, and big promise and subsequent failure of renal denervation solution has cut the growth among other device manufacturers. There are challenges across the board from development to commercialization, said Judelson. Hospitals are faring no better. Nearly 40% of California hospitals received bad grade, constant M&A activity among hospitals, pressure from changing government initiatives, difficulties with privacy and security of EMR data has all led to medical device companies spending more money to get less and spending more in sales and marketing efforts is not the answer.
Five current headwinds are defining the existing environment. Increased regulation and declining reimbursement from fee for service to bundling and changes in how CMS pays, is putting a lot of pressure on providers who pass the burden on to device manufacturers. Second, there is a lot of variability in how different hospitals measure quality. Third, aging population with increasing co-morbidities is leading to variability in clinical trials and making it challenging to assess the effects of interventions. Four, challenges are increasing with decreasing hospital access for sales reps. Five, huge global volatility with large swings in foreign exchange rates, government uprisings etc. is making it hard to estimate earnings.
Hospitals are often burdened with internal challenges of system integration, promise and challenges of mobile technology, problems of achieving seamless inter-operability, thinning margins, vendor management issues, physicians getting overburdened with administrative tasks, HIPPA issues and more. All these challenges are compounded with sub par performance from medical device companies as they are delivering more failures in R&D, demonstrating lack of innovation with decreased ROI followed by decreasing investment in venture and M&A activity.
Currently, there are few solutions for comprehensive customer management, said Judelson. Some general solutions like Salesforce, Oracle, imshealth, freshdesk, Veeva and Zendesk have been applied. However, these require significant customization, often have complex pricing structure, are pricey for small to mid-sized enterprises, have complex IT integration and archaic mobile user interface, and are often based on limited knowledge of medical device econsyste. There are no existing CRM solutions specially designed for medical device industry, said Judelson.
VirtuMed’s cloud based remote connectivity solution specifically fills in this gap, where device manufacturers can establish direct line with the customer, provide better, more timely customer support as a value added service, develop apps, and leverage knowledge of product users globally with access to real time outcomes data. There are many gains from such timely information. Research indicates that with timely physician access to post surgery recovery process and real-time conversation with patients, recovery occurs faster and patients remain more engaged in their recovery. While there is a great deal of patient to patient interaction in social media, there are fewer tools for patient to provider engagement and that needs to change.
VirtuMed’s Synapse mobile solution helps build a connected ecosystem that combines commercial CRM, social networking, on demand communication, big data visualization, HIPPA compliant infrastructure, and enhances security with data changing hands while ensuring availability of data at the right time to the right people. This solution aims to unite all key stakeholders on a single platform with primary objective for positive patient impact, said Krishna. VirtuMed product is poised to offer support to companies of any size and its tech solutions can be applied at each stage in medical device life cycle, from early innovation to clinical stakeholder engagement, to customer engagement to CRM platform to enable growth in emerging markets; literally from ideation to discovery to clinical to commercialization, said Krishna.
The talk with followed with Q&A.
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship on April 7, 2015
Internet of Things is a hyped up buzz word but it is not without challenges. First and foremost it requires innovative ways to sense and deliver information from the physical world to the cloud. Power is also a critical element. Many IoT applications need an ability to run for years over batteries and reduce overall energy consumption. MediaTek is one of the largest chip-design companies providing system-on-chip solutions for the global market. Johan Lodenius, Corporate VP and Chief Marketing Officer at MediaTek, will give an opening keynote in IoT track at TiEcon 2015.
MediaTek excels in achieving tight integration of components, rendering technology more efficient, enabling rich set of features, with less resources, and making it more affordable. The company began with designing chipsets for optical drives and later expanded into chip solutions for DVD players, digital TVs, mobile phones, smart phones, tablets and so on. In about seven years from launch, the company has gained huge market share worldwide. In 2014, the company posted revenues of 213.1 B TWD, about USD $ 6.88 B.
The company has been known to provide extensive system engineering assistance that enables many smaller players and new entrants to enter a mobile market that has been thus far dominated by large corporations. Looking forward to words of wisdom from Lodenius on how entrepreneurs can overcome the challenges of IoT market and better understand areas of opportunities. Register at https://www.123signup.com/register?id=ygszb&ref=4182698 to get a $100 discount on the two-day conference at the non-member rate. When prompted, enter the promo code VOL500 at checkout.
EPPIC annual conference is on March, 28 and early bird pricing will end on Monday, March 16. Here is a sneak peek at one of the panels.
Technology is impacting health in interesting ways and many exciting innovations in digital health are expected to change how diseases are tracked, reduce inefficiency in healthcare delivery, reduce costs, improve access to healthcare, increase quality, save resources, and make medicine more personalized. Digital health panel at EPPICon 2015 has diverse and interesting lineup of speakers.
Dr. David Persing, EVP, CMO, and CTO at Cepheid, had made an early resolve to have a positive impact on the world. Guided by intellectual curiosity, while doing his pre-med, he discovered “the power of diagnostics”. The company’s mission at Cepheid is to use the power of molecular diagnostics such that it would enable medical providers to identify and treat diseases early, increasing opportunities to improve patients’ survival and quality of life. Their cloud based platform, “The Digital Miasma” for monitoring of emerging infections earlier, is just launched and is in the implementation phase.
Panelist Deborah Profit is Director of Corporate Projects – Global Clinical & Business Operations for Otsuka Pharmaceutical Development and Commercialization. OPC, is headquartered in Tokyo and is known for popular sports drink Pocari Sweat and energy drink Oronamin C. OPC also developed Abilify, an approved drug treatment for certain mental illnesses, and as of 2013, annual sales of Abilify were over $8 billion a year, making it the highest grossing drug worldwide. You would wonder what has that to do with digital health, until you consider the fact that patient non-compliance is one of the biggest challenges in many illnesses but specifically in mental illnesses. Otsuka has recently made a deal with Proteus Digital Health for tracking medical adherence. Proteus system includes sensor-enabled pills that embed intelligence into the pills so that their ingestion can be precisely tracked. Personally, I am totally against drugs for mental illnesses, many of which do not work as expected; placebo effects are not well identified, clinical studies are often sponsored by drug companies and the list of side effects is daunting and being a psychologist, having seen side effects and heard them being discussed by my colleagues, I have developed absolute disgust for drugs for mental disorders.
Proteus “ingestible sensor” technology however, holds enormous promise for various indications, specifically for treatment and management of chronic conditions. Otsuka plans to make use of Proteus Digital Health’s feedback system in its clinical R&D, presumably for its oncology products.
The next panelist, Dr. Marsha Rose Gillentine is Director of Biotechnology/ Chemical Group at Sterne Kessler Goldstein Fox, LLP and has intimate knowledge and understanding of patent litigation strategy in small molecules, ploymorphs, chemical synthesis, pharmaceutical formulations, methods of treatment, drug delivery devices, animal models, vaccines, polymers and more. Her experience encompasses working with clients to implement lifecycle management strategies, specifically at it relates to personalized medicine patent portfolios.
Jared Heyman is founder and CEO of CrowdMed, a brilliant innovative site that takes connected health to a whole new plane. Often individuals afflicted with rare or neglected diseases, go from doctor to doctor, from pillar to post, just to accurate diagnosis and then they face whole set of new challenges for treatment. CrowdMed is seeking to solve most challenging medical cases, worldwide, with speed and accuracy online, by harnessing the collective wisdom of the crowd.
The Digital Health Panel at EPPICon 2015, will be an exciting panel. Agenda for the entire day looks very interesting and there will be plenty of opportunities for attendees to network and mingle with like-minded professionals. The conference is on Saturday, March 28th at Santa Clara Convention Center, in Santa Clara, CA. Early bird pricing has been extended till March, 16. Please register for the event at the link http://tinyurl.com/o4cj3ow or from www.eppicglobal.org .
Posted by Darshana V. Nadkarni, Ph.D. in Big Data -Cloud -IoT-Software -Mobile -Entrepreneurship, Biotech - Medical Device - Life Science - Healthcare on February 27, 2014
Al Gicqueau, CEO & President at Clinovo talked about Cloud-based eClinical Systems to make clinical trial process more efficient and cost-effective, at www.bio2devicegroup.org event.
Cloud has been a big buzz word, significantly impacting the economy, in the last few years. Cloud is growing 3X faster than traditional internet infrastructure, said Gicqueau. Worldwide public cloud services market will total to over $73 billion, by 2017. There is also simultaneous cloud-bashing. According to Citrix research, majority of the Americans don’t understand it and over 51% think it has something to do with the stormy weather. Most also believe they have never used it but over 95% of us have used cloud based services.
It is therefore important to understand what constitutes cloud based services. There are 5 essential components of cloud based services.
Self Service, On Demand: Cloud based services are available, when the consumer needs them. Further, for the most part they are autonomous and the user can perform the actions without going through the IT department. They are easy to use and on-site training will increasingly become a thing of the past. Any training required has to be available on-line and has to be very short and for the most part the service has to be intuitive and should not require training.
Broad Network Access: Cloud based services provide a broad internet access. For instance, consider gmail. It can be accessed through desktop, laptop, tablet, smart phone etc. Cloud based services enable an ability to easily synchronize information over multiple devices.
Resource Pooling: Amount of traffic over the internet is rapidly growing. Because of the distributed nature of the internet, there is no single point of measurement for total internet traffic. But it is a fact that the total global IP traffic will pass the zettabyte threshold by the end of 2015. By the year 2017, the total internet traffic is expected to reach 5.3 zettabytes. To put it in perspective, if the 11 oz coffee on your desk equals one gigabyte, a zettabyte will have the same volume as the great wall of China! Cloud based services enable customers to pool their resources and save cost.
Rapid Elasticity: In the world of internet activity there are lot of peaks and valleys. Cloud can scale based on demand peaks, without incurring penalty for the period of low traffic.
Measured Service: Cloud offers and ability to pay as you go. People can pay for the internet infrastructure as they pay for electricity.
Some of the examples of cloud based services include, SalesForce, Netflix, Gmail and Amazon.
Clinical Data Trends
Spiraling costs have been a grave concern in healthcare. Typically, efficiency has not been very high in the area of healthcare. Costs of clinical trials is likely to increase even more significantly, in future, on account of increasing costs of medical research and changing and tightening regulations, among other things. Increased costs for clinical trials will push the cost of drugs higher. On the other hand, there is strong public criticism of higher costs of medicines and there is a lot of pressure on drug companies to contain costs. Companies have pressure to cut the middle layers and manage clinical trials on their own. Citing CISCRP (Center for Information & Study on Clinical Research Participation) study, Gicqueau said, currently, only 6% of clinical trials are completed on time, whereas 72% run late by over a month.
Compliance issues and regulations specified in 21 CFR, part 11, prohibit use of public cloud, for clinical data. Clinical data has to be stored in a private cloud. Clinovo’s ClinCapture is a cost-effective EDC (electronic data capture) system. It is tailored to specific clinical studies teams and offers intuitive navigation and one-click access to routine functions. It reduces time for data entry. ClinCapture is also flexible and can be customized and deployed rapidly. “We validate our software like medical devices are validated”, said Gicqueau.
Mobile is next major trend, as more data entries are happening through tablets and smart phones. Tables are also very useful in remote regions of the world where cell phone reception may be spotty or non existent, where information can be easily synchronized later. Data entries can also be structured by getting patients involved. Data integration is another big challenge. Everyone hopes to make sense of the data and make meaningful use of the data. However, making sense of the data and putting it to good use remains expensive. Gicqueau said, meaningful data integration is another promise of the cloud.
Clinovo is launching CloudClinica, next generation, cloud-based eClinical platform. With its easy to use, pay as you go platform, CloudClinica will eliminate IT dependency and allow small companies to manage clinical studies in a sophisticated manner, without high level programming skills. About 30% of cost and 60% of time associated with clinical trials is about data management, and almost 80% of clinical trials are still conducted on paper, said Gicqueau. Paper has many pitfalls. Paper can get lost, it is inefficient, there is challenge of mis-reading someone’s handwriting, it has regulatory risks and other hidden costs. CloudClinica is FDA compliant and it can scale.
Clinovo had revenues of over $4 million in 2013 and raised $500,000 from business angels over the last few months to execute on their business strategy. The company is profitable, and has 30+ clients that include Gilead, Roche and others. Clinovo is now targeting small to mid-size companies, said Gicqueau. Current market of $2.3 billion can be rapidly growing in the coming years. MediData and Oracle are two dominant players but are relatively more pricey. Clinovo’s CloudClinica will fill in the gap and broaden the use of eClinical systems and will empower and bolster the biotech, pharmaceutical, and medical device companies, said Gicqueau. The event was followed by Q&A.
Posted by Darshana V. Nadkarni, Ph.D. in Biotech - Medical Device - Life Science - Healthcare on February 5, 2014
Mahendra Shah, Partner with Vivo Ventures & Ravi Mistry, President of EPPICGLOBAL (www.eppicglobal.org) talked about how to take a biotech company from idea to launch, at www.bio2devicegroup.org event. Here is some of the comments made by Shah and Mistry.
Entrepreneurs starting a biotech company must start with a disease target, said Shah. First and foremost there should have a good understanding of the disease and at which stage in the disease progression is the biotech seeking to interfere. Second, one should have a good understanding of the market opportunity and about existing treatments. Entrepreneurs need to ask the hard question regarding “clinical meaningfulness”; and whether or not the possible treatment developed by the biotech will lead to significant enhancement in patient care. Payers will not pay for little improvements, said Shah. Companies need to identify gaps in the treatment, and find a niche market. Patients need to be identified for who the prescribed treatments do not work well and that could be a niche market for entrepreneurs, said Shah. Shah said that during his career, he found such niche markets through repurposing, taking old drugs and finding new indications. He also cautioned about the importance of ensuring secure Intellectual Property to protect the proposed solution. With currently available internet tools and database resources, that is not hard to do. Even speed browsing on Google can give you a quick idea of who owns the IP and if there are ways to get around it, said Shah. Biotechs based on developing Orphan drugs are a great opportunity for a new startup, because once approved, you cannot have competition for up to 7 years in the US, and up to 10 years in Europe.
In terms of drug development, one needs to also get clarity on development pathway to determine whether it will require 10 thousand patients or few hundred, since that can make a huge difference in the amount of financial capital that will be required to bring the product to market. Companies need to identify how quickly one can progress to phase 2 and bring it to a meaningful endpoint. Also it is important to get an understanding if the endpoint is subjective or objective. A subjective endpoint will have significant placebo effect and will require much higher number of patients, said Shah. In order to do successful fund raising, companies need to have approximate idea of time and costs of bringing the product opportunity to a meaningful endpoint. Companies also need to have clarity on the various product development milestones and inflection points. Finally, an experienced Team is extremely important to bring the idea to fruition. However in this, two members of the team are particularly important; the CEO and the Medical Director. Other members of the management team can be hired as consultants but these two team members of the team need to be identified early and brought on board and should be people one can trust and those who feel passionate about the technology and who buy into it.
A biotechnology company requires significant money for its operations, so it is important to make sure that the first time investors have deep pockets, very sane advice from Shah. He told the budding entrepreneurs to be careful and make sure they have synergy with the investors. “Some of the investors’ money is not good, it will give you ulcers”, warned Shah, since money can have many strings attached to its return on investment. Referring to reimbursement, Shah emphasized that the payer is very important and entrepreneurs should do a quick survey of physicians and Key Opinion and Thought Leaders and get a clear idea about existing and current modes of treatment and who will be paying for the new product opportunity.
Mistry shared some statistics on activity in the life science space. 2013 has been a banner year for life science IPOs. Out of a total of 82 total IPOs in 2013, 46 were in the life science industry. Life science industry also enjoyed a substantial investment of dollars. The increase was certainly more significant in biotechnology, while medical device industry actually saw fewer dollars invested. Mistry talked about how to prepare for an M&A exit and provided some advice to entrepreneurs to keep diligent documentation with respect to company’s IP. He also commented that when it comes to negotiation, there is no “one size fits all” and best deals can be made if entrepreneurs remain can remain flexible throughout the process.
At the start of the talk Mistry put in a plug for EPPICGlobal and their upcoming annual conference, on March 29, 2014. The conference has an exciting lineup of speakers and panels addressing neglected and rare diseases, point of care diagnostics, and innovations in clinical development of novel agents. The talk ended with Shah sharing information on exciting speed pitch session, at the EPPIC conference, where entrepreneurs will have an opportunity to pitch their company to a panel of VCs and receive real-time feedback.
I would encourage my readers to attend the EPPICon 2014 conference, and avail of the opportunity to listen to various industry renowned speakers. To register for the conference and/or register for the speed pitch, please go to www.eppicglobal.org.